Literature DB >> 18694938

Endocannabinoids and the control of energy homeostasis.

George Kunos1, Douglas Osei-Hyiaman, Jie Liu, Gregorz Godlewski, Sándor Bátkai.   

Abstract

Endocannabinoids (ECBs) are ubiquitous lipid mediators that act through the same G protein-coupled receptors (CB1 and CB2) that recognize plant-derived cannabinoids. As regulators of metabolism, ECBs are anabolic: they increase the intake, promote the storage, and decrease the expenditure of energy. Recent work indicates that activation of peripheral CB1 receptors by ECBs plays a key role in the hormonal/metabolic changes associated with obesity/metabolic syndrome and may be targeted for its pharmacotherapy.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18694938      PMCID： PMC2586261          DOI： 10.1074/jbc.R800012200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN： 0021-9258            Impact factor:   5.157


  64 in total

1.  SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset.

Authors:  J Simiand; M Keane; P E Keane; P Soubrié
Journal:  Behav Pharmacol       Date:  1998-03       Impact factor: 2.293

2.  Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors.

Authors:  M Arnone; J Maruani; F Chaperon; M H Thiébot; M Poncelet; P Soubrié; G Le Fur
Journal:  Psychopharmacology (Berl)       Date:  1997-07       Impact factor: 4.530

3.  Antifibrogenic role of the cannabinoid receptor CB2 in the liver.

Authors:  Boris Julien; Pascale Grenard; Fatima Teixeira-Clerc; Jeanne Tran Van Nhieu; Liying Li; Meliha Karsak; Andreas Zimmer; Ariane Mallat; Sophie Lotersztajn
Journal:  Gastroenterology       Date:  2005-03       Impact factor: 22.682

4.  Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP.

Authors:  Jiandie Lin; Ruojing Yang; Paul T Tarr; Pei-Hsuan Wu; Christoph Handschin; Siming Li; Wenli Yang; Liming Pei; Marc Uldry; Peter Tontonoz; Christopher B Newgard; Bruce M Spiegelman
Journal:  Cell       Date:  2005-01-28       Impact factor: 41.582

5.  Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells.

Authors:  V Di Marzo; L De Petrocellis; N Sepe; A Buono
Journal:  Biochem J       Date:  1996-06-15       Impact factor: 3.857

6.  Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice.

Authors:  Y L Liu; I P Connoley; C A Wilson; M J Stock
Journal:  Int J Obes (Lond)       Date:  2005-02       Impact factor: 5.095

7.  The anti-obesity effect of rimonabant is associated with an improved serum lipid profile.

Authors:  B Poirier; J-P Bidouard; C Cadrouvele; X Marniquet; B Staels; S E O'Connor; P Janiak; J-M Herbert
Journal:  Diabetes Obes Metab       Date:  2005-01       Impact factor: 6.577

8.  Appetite suppression and weight loss after the cannabinoid antagonist SR 141716.

Authors:  G Colombo; R Agabio; G Diaz; C Lobina; R Reali; G L Gessa
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

9.  Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice.

Authors:  Douglas Osei-Hyiaman; Jie Liu; Liang Zhou; Grzegorz Godlewski; Judith Harvey-White; Won-il Jeong; Sándor Bátkai; Giovanni Marsicano; Beat Lutz; Christoph Buettner; George Kunos
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

Review 10.  Life without neuropeptide Y.

Authors:  R D Palmiter; J C Erickson; G Hollopeter; S C Baraban; M W Schwartz
Journal:  Recent Prog Horm Res       Date:  1998
View more
  42 in total

1.  Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice.

Authors:  Jie Liu; Liang Zhou; Keming Xiong; Grzegorz Godlewski; Bani Mukhopadhyay; Joseph Tam; Shi Yin; Peter Gao; Xin Shan; James Pickel; Ramon Bataller; James O'Hare; Thomas Scherer; Christoph Buettner; George Kunos
Journal:  Gastroenterology       Date:  2012-01-31       Impact factor: 22.682

2.  Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages by activated organophosphorus insecticides: role of carboxylesterases 1 and 2.

Authors:  Shuqi Xie; Abdolsamad Borazjani; M Jason Hatfield; Carol C Edwards; Philip M Potter; Matthew K Ross
Journal:  Chem Res Toxicol       Date:  2010-12-20       Impact factor: 3.739

Review 3.  Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.

Authors:  Rosa Zampino; Aldo Marrone; Luciano Restivo; Barbara Guerrera; Ausilia Sellitto; Luca Rinaldi; Ciro Romano; Luigi E Adinolfi
Journal:  World J Hepatol       Date:  2013-10-27

Review 4.  The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications.

Authors:  Lydia K Miller; Lakshmi A Devi
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

5.  Global deletion of MGL in mice delays lipid absorption and alters energy homeostasis and diet-induced obesity.

Authors:  John D Douglass; Yin Xiu Zhou; Amy Wu; John A Zadroga; Angela M Gajda; Atreju I Lackey; Wensheng Lang; Kristen M Chevalier; Steven W Sutton; Sui-Po Zhang; Christopher M Flores; Margery A Connelly; Judith Storch
Journal:  J Lipid Res       Date:  2015-04-04       Impact factor: 5.922

Review 6.  Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases.

Authors:  Joyce M Richey; Orison Woolcott
Journal:  Curr Diab Rep       Date:  2017-09-14       Impact factor: 4.810

7.  Racial and sex differences in the polymorphisms of the endocannabinoid receptor genes in obesity.

Authors:  Tina K Thethi; Aster Sigel; Shanker Japa; Bonnie Katalenich; Shuqian Liu; Tuyen Nguyen; Joshua Larrazolo; Stephanie Syu; Esther Carefoot; Roberta McDuffie; Vivian Fonseca
Journal:  J Diabetes Complications       Date:  2020-07-17       Impact factor: 2.852

8.  Hepatitis C virus induces the cannabinoid receptor 1.

Authors:  David van der Poorten; Mahsa Shahidi; Enoch Tay; Jayshree Sesha; Kayla Tran; Duncan McLeod; Jane S Milliken; Vikki Ho; Lionel W Hebbard; Mark W Douglas; Jacob George
Journal:  PLoS One       Date:  2010-09-17       Impact factor: 3.240

9.  Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist.

Authors:  John R Hadcock; Philip A Carpino; Philip A Iredale; Robert L Dow; Denise Gautreau; Lucinda Thiede; Dawn Kelly-Sullivan; Jeffrey S Lizano; Xingrong Liu; Jeffrey Van Deusen; Karen M Ward; Rebecca E O'Connor; Shawn C Black; David A Griffith; Dennis O Scott
Journal:  BMC Pharmacol       Date:  2010-08-16

10.  Biomarkers of endocannabinoid system activation in severe obesity.

Authors:  Jack C Sipe; T Michael Scott; Sarah Murray; Olivier Harismendy; Gabriel M Simon; Benjamin F Cravatt; Jill Waalen
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.